Search Results
Mar 30, 2026, 08:00 ET Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
as we continue to advance partnerships, drive innovation and create long-term value from our technology."Dr. Walker succeeds Dr. Ruxandra Draghia-Akli, who has departed the Company to pursue other opportunities. In his new role, Dr. Walker will oversee Novavax's preclinical and clinical research
More news about: Novavax, Inc.
Nov 04, 2025, 13:14 ET INTREPID Alliance Launches Antiviral Toolbox to Support Global Research Community
www.intrepidalliance.org. 1 Draghia-Akli, R, et al. The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness. Clinical Infectious Diseases, 2025.
More news about: INTREPID Alliance
Nov 04, 2025, 12:55 ET INTREPID Alliance Launches Antiviral Toolbox to Support Global Research Community
www.intrepidalliance.org. 1 Draghia-Akli, R, et al. The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness. Clinical Infectious Diseases, 2025.
More news about: INTREPID Alliance
Jul 24, 2025, 08:00 ET Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
strength of our technology platform and our ability to deliver against our corporate growth strategy," said Ruxandra Draghia-Akli, MD, PhD, Executive Vice President and Head of Research and Development, Novavax. "Our R&D pipeline focuses on delivering assets ready for
More news about: Novavax, Inc.
Jun 11, 2025, 07:00 ET Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
combination and stand-alone flu vaccine candidates induced robust immune responses and were well tolerated," said Ruxandra Draghia-Akli, MD, PhD, Executive Vice President and Head of Research and Development, Novavax. "This data set adds to findings from our Phase 2 trial and
More news about: Novavax, Inc.